Masitinib (4.5) · Oncology, Immunology, Neurology Masitinib is a tyrosine kinase inhibitor that selectively targets c-KIT, PDGFR, and Lyn kinases to modulate immune cell function and reduce pathological inflammation.
Masitinib (6.0) · Neurology, Immunology, Oncology Masitinib is a tyrosine kinase inhibitor that selectively targets c-Kit, PDGF receptor, and Lyn kinase to modulate immune cell activation and reduce inflammatory responses.
Riluzole (100 mg) · Neurology Riluzole reduces glutamate excitotoxicity by inhibiting glutamate release and blocking sodium channels in neurons.
Phase 2 pipeline
AB1010 · Oncology AB1010 is a small molecule that targets the PI3K pathway.